Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE

News

Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.

READ MORE

Patients with rheumatoid arthritis are at increased risk of serious infections, myocardial infarction, and coronary heart disease, an analysis of Medicare claims data suggests.

READ MORE

Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.

READ MORE

As initial therapy for relapsing-remitting multiple sclerosis, rituximab works better than commonly used disease-modifying treatments, hint results of a comparative real-world effectiveness study from Sweden.

READ MORE

Research in Review

A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.

READ MORE

Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.

READ MORE

Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.

READ MORE

A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.

READ MORE

Resources

The first guidelines on the use of disease-modifying therapies in multiple sclerosis have been issued by the European Committee for Research and Treatment of Multiple Sclerosis and the European Academy of Neurology.

READ MORE